SARS-CoV-2 Binding and Neutralization Properties of Peptides Derived from N-Terminus of Human ACE2
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24098269 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Irina V Astrakhantseva und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Immunobiology and Biomedicine, Sirius University of Science and Technology, Sirius, Krasnodarsky Krai, 354349 Sochi, Russia. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Higher Education of Russian Federation, Russian Foundation for Basic Research, Ministry of Science and Higher Education of the Russian Federation.
Abstract (Originalsprache)
The binding properties of synthetic and recombinant peptides derived from N-terminal part of ACE2, the main receptor for SARS-CoV-2, were evaluated. Additionally, the ability of these peptides to prevent virus entry in vitro was addressed using both pseudovirus particles decorated with the S protein, as well as through infection of Vero cells with live SARS-CoV-2 virus. Surprisingly, in spite of effective binding to S protein, all linear peptides of various lengths failed to neutralize the viral infection in vitro. However, the P1st peptide that was chemically “stapled” in order to stabilize its alpha-helical structure was able to interfere with virus entry into ACE2-expressing cells. Interestingly, this peptide also neutralized pseudovirus particles decorated with S protein derived from the Omicron BA.1 virus, in spite of variations in key amino acid residues contacting ACE2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Immunobiology and Biomedicine, Sirius University of Science and Technology, Sirius, Krasnodarsky Krai, 354349 Sochi, Russia.
- Laboratory of Gene Therapy of Socially Significant Diseases, Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology, Russian Academy of Sciences, 119334 Moscow, Russia.
- Department of Emerging and Reemerging Infections, Chumakov Scientific Center for Research and Development of Immune-and-Biological Products, Russian Academy of Sciences (Institute of Poliomyelitis), 108819 Moscow, Russi…
- Institute for Translational Medicine and Biotechnology, Sechenov First Moscow State Medical University (Sechenov University), 119435 Moscow, Russia.
- Laboratory of Molecular Mechanisms of Immunity, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.
ORCID-Profile: Alina E Ershova, Natalia A Kruglova
Förderung
- Ministry of Science and Higher Education of Russian Federation
- Russian Foundation for Basic Research
- Ministry of Science and Higher Education of the Russian Federation
Zitieren
APA
Astrakhantseva, I. V., Ershova, A. E., Chuvpilo, S. A., Kruglova, N. A., Ishmukhametov, A. A., Drutskaya, M. S., Kozlovskaya, L. I., & Nedospasov, S. A. (2023). SARS-CoV-2 Binding and Neutralization Properties of Peptides Derived from N-Terminus of Human ACE2. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24098269
Vancouver
Astrakhantseva IV, Ershova AE, Chuvpilo SA, Kruglova NA, Ishmukhametov AA, Drutskaya MS, et al. SARS-CoV-2 Binding and Neutralization Properties of Peptides Derived from N-Terminus of Human ACE2. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24098269
BibTeX
@article{Astrakhantseva2023,
author = {Astrakhantseva, Irina V and Ershova, Alina E and Chuvpilo, Sergei A and Kruglova, Natalia A and Ishmukhametov, Aydar A and Drutskaya, Marina S and Kozlovskaya, Liubov I and Nedospasov, Sergei A},
title = {SARS-CoV-2 Binding and Neutralization Properties of Peptides Derived from N-Terminus of Human ACE2},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24098269}
}
EUVIMED